RT Journal Article
SR Electronic
T1 Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1153
OP 1160
DO 10.21873/anticanres.14057
VO 40
IS 2
A1 MANATO OHSAWA
A1 YOICHI HAMAI
A1 MANABU EMI
A1 FURUKAWA TAKAOKI
A1 YUTA IBUKI
A1 KUROKAWA TOMOAKI
A1 TORU YOSHIKAWA
A1 MORIHITO OKADA
YR 2020
UL http://ar.iiarjournals.org/content/40/2/1153.abstract
AB Background/Aim: Neoadjuvant therapy followed by surgery is the standard treatment for advanced esophageal cancer. This study aimed to evaluated the potential of 18F-fluorodeoxyglucose positron-emission tomography to predict the pathological therapeutic effect of neoadjuvant chemotherapy. Patients and Methods: We enrolled 68 patients with advanced esophageal squamous cell carcinoma who underwent 18F-fluorodeoxyglucose positron-emission tomography before and after neoadjuvant chemotherapy, followed by surgery. Retrospective analysis of the pathological therapeutic effects was performed. Results: The pathological therapeutic effect of good responders was significantly inversely associated with the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy and with SUVmax reduction (both p<0.0001). Univariate and multivariate analyses revealed that lower post therapy SUVmax and reduction in SUVmax were independent prognostic factors for relapse-free (p=0.02) and overall survival (p<0.0001). Conclusion: Post-neoadjuvant chemotherapy SUVmax and SUVmax reduction can predict the pathological therapeutic effect of neoadjuvant chemotherapy.